ONCS


OncoSec Prices $15M Offering; Analyst Sees Further 150% Upside Ahead

Late-stage biotech OncoSec Medical (ONCS) has announced that it has entered into purchase agreements for an aggregate 4,608,589 of its shares at an offering …

3 “Strong Buy” Penny Stocks With Triple-Digit Upside Potential

Are penny stocks a must-have or a must-avoid? Well, that depends on who you ask.

Why OncoSec Medical (ONCS) Stock Crashed Today

Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …

OncoSec Medical Inc (ONCS) Hits New Record Highs; Here’s Why

It’s a very rewarding trading day for investors in OncoSec Medical Inc (NASDAQ:ONCS) with shares up over 180%, making the stock Wall Street’s …

Maxim Weighs in on OncoSec Medical Inc (ONCS) Ahead of Immune Data Presentation

OncoSec Medical Inc (NASDAQ:ONCS) shares are rising almost 8% ahead of the biotech firm’s immune data presentation tomorrow at the American Association for …

Stock Update (NASDAQ:ONCS): OncoSec Medical Inc Announces Fourth Quarter and Year End Results for Fiscal Year 2016

OncoSec Medical Inc (NASDAQ:ONCS) announced financial results for the fourth quarter and fiscal year ended July 31, 2016. “During the fourth quarter, we continued …

Company Update (NASDAQ:ONCS): OncoSec Medical Inc Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer

OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced Sharron Gargosky, PhD, has been appointed to Chief Clinical and Regulatory …

Company Update (NASDAQ:ONCS): OncoSec Medical Inc Presents Preliminary Findings from Head and Neck Phase II Clinical Trial at EUROGIN 2016 Conference

OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented preliminary findings from OMS-I130, a Phase II clinical trial of ImmunoPulse™ …

Stock Update (NASDAQ:ONCS): OncoSec Medical Inc Closes $10 Million At-The-Market Registered Direct Offering

OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has closed its previously announced at-the-market registered direct offering …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts